Contrasting ProSomnus (OSA) & The Competition

ProSomnus (NASDAQ:OSA) is one of 229 publicly-traded companies in the “Surgical & medical instruments” industry, but how does it compare to its competitors? We will compare ProSomnus to related companies based on the strength of its analyst recommendations, valuation, risk, dividends, institutional ownership, profitability and earnings.

Profitability

This table compares ProSomnus and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ProSomnus	-87.14%	N/A	-106.30%
ProSomnus Competitors	-739.20%	-147.41%	-28.97%

Institutional & Insider Ownership

70.0% of ProSomnus shares are held by institutional investors. Comparatively, 48.8% of shares of all “Surgical & medical instruments” companies are held by institutional investors. 7.7% of ProSomnus shares are held by insiders. Comparatively, 15.4% of shares of all “Surgical & medical instruments” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Valuation and Earnings

This table compares ProSomnus and its competitors revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
ProSomnus	$27.65 million	-$24.09 million	-0.09
ProSomnus Competitors	$1.04 billion	$3.84 million	-7.87

ProSomnus’ competitors have higher revenue and earnings than ProSomnus. ProSomnus is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Analyst Recommendations

This is a summary of recent recommendations and price targets for ProSomnus and its competitors, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProSomnus	0	1	2	0	2.67
ProSomnus Competitors	1596	4308	8443	223	2.50

ProSomnus currently has a consensus price target of $2.33, indicating a potential upside of 1,566.67%. As a group, “Surgical & medical instruments” companies have a potential upside of 28.75%. Given ProSomnus’ stronger consensus rating and higher probable upside, research analysts clearly believe ProSomnus is more favorable than its competitors.

Risk & Volatility

ProSomnus has a beta of 0.21, meaning that its stock price is 79% less volatile than the S&P 500. Comparatively, ProSomnus’ competitors have a beta of 1.13, meaning that their average stock price is 13% more volatile than the S&P 500.

Summary

ProSomnus beats its competitors on 7 of the 13 factors compared.

ProSomnus Company Profile

ProSomnus, Inc. operates as a medical technology company that develops, manufactures, and markets precision intraoral medical devices for treating and managing patients with obstructive sleep apnea. The company sells its products to sleep dentists, sleep physicians, primary care providers, otolaryngologists, and other integrated healthcare service providers through a direct sales force. ProSomnus, Inc. is headquartered in Pleasanton, California.